Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
06. Februar 2020 08:11 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
Amarantus Releases Letter to Shareholders
04. Februar 2020 09:54 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
30. Januar 2020 09:05 ET
|
Amarantus Bioscience Holdings, Inc.
Strong customer retention at both stores in Dallas, TX with growing online presence Focus on delivering wellness solutions by engaging customers to participate in clinical studies and provide...
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
02. Januar 2020 08:14 ET
|
Amarantus Bioscience Holdings, Inc.
Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02,...
Amarantus to Present at 12th Annual LD Micro Main Event
09. Dezember 2019 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, NY, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
04. Dezember 2019 07:36 ET
|
Amarantus Bioscience Holdings, Inc.
· Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS)...
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
21. November 2019 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC...
Amarantus Provides Recapitalization Update to Shareholders
18. November 2019 08:30 ET
|
Amarantus Bioscience Holdings, Inc.
Pending license with Emerald provides opportunity to realize therapeutic portfolio valueJV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical trialAmarantus management...
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
24. Oktober 2019 09:34 ET
|
Amarantus Bioscience Holdings, Inc.
Amarantus is receiving Emerald Preferred Stock with a minimum value of $100M in 2022 Treatment candidates are for Alzheimer’s, ADHD, Parkinson’s, severe burns and vision loss Portfolio includes...
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
25. Juni 2019 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, NY, June 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...